Gilead
Health groups want India to rescind Gilead drug patents
Advocacy groups want remdesivir to be distributed more fairly to coronavirus patients around the world.
Gilead's three-drug HIV regimen wins European panel approval
Biktarvy is once-daily tablet combining emtricitabine, tenofovir alafenamide and integrase inhibitor bictegravir.
Gilead triple HIV drug finds US FDA approval
However, rival ViiV Healthcare, quickly filed a lawsuit alleging that Gilead was infringing patents on ViiV’s dolutegravir.
1 of 1